Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Emily Field, head of European pharmaceuticals research at Barclays, weighs in on rising competition in the global obesity ...

Prescriptions of obesity management drugs (OMDs) have increased, and these increasing trends are associated with online ...

The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

Eli Lilly shares rose more than 1% premarket Thursday, on track to hit levels last seen in late October, as the ...

The ad violates federal rules requiring “that advertising for prescription drugs – including compounded drugs – not be false ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...